The AffloVest is battery-operated and uses Direct Dynamic Oscillation technology, which closely mimics hand CPT (Chest Physical Therapy) to help mobilise and clear secretions from the lungs, and allows for full freedom of mobility during treatment.
Doctors prescribe AffloVest for patients across a range of ages who have severe respiratory diseases such as bronchiectasis, cystic fibrosis, and certain neuromuscular diseases.
This next generation AffloVest, which began shipping September 1, is much lighter, quieter, and more efficient, with a smaller profile battery and long-life, state-of-the-art motors, offering improved patient ease of use.
The new AffloVest is on average 2 pounds lighter (more than 20% less weight) than the previous version, and uses streamlined components and tailored styling for a sleeker, slimmer fit.
International Biophysics brings to market medical devices and technologies aimed at improving treatment therapies and patient outcomes.
The company's precision ISO 13485 certified, FDA registered, quality controlled US manufacturing facility is located in Austin, Texas.
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Neola Medical secures US patent for disposable lung monitoring probes
Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302
Polarean expands XENOVIEW 3T Coil access with Philips compatibility
Immedica gets UAE approval for Zepzelca maintenance treatment